Table 2.
Long-term efficacy of etanercept in patients with r-axSpA (n = 12) and nr-axSpA (n = 7), who completed 10 years of the ESTHER trial.
| Outcomes | Baseline | Week 24 | Year 1 | Year 2 | Year 3 | Year 4 | Year 6 | Year 8 | Year 10 | |
|---|---|---|---|---|---|---|---|---|---|---|
| BASDAI, 0–10, mean (SD) | r-axSpA | 5.0 (0.7) | 2.4 (1.6) | 2.3 (2.1) | 1.9 (1.8) | 1.5 (1.5) | 1.8 (1.7) | 1.6 (1.2) | 1.6 (1.7) | 1.9 (1.9) |
| nr-axSpA | 6.2 (1.4) | 3.2 (2.4) | 2.3 (1.8) | 1.7 (1.8) | 1.2 (1.0) | 1.0 (0.8) | 1.2 (0.8) | 1.3 (0.8) | 1.4 (1.1) | |
| BASFI, 0–10, mean (SD) | r-axSpA | 3.5 (1.8) | 1.4 (1.2) | 1.8 (1.5) | 1.5 (1.8) | 1.4 (1.5) | 1.4 (1.6) | 1.5 (1.5) | 1.6 (1.9) | 1.6 (1.9) |
| nr-axSpA | 4.7 (2.6) | 2.2 (2.0) | 1.6 (1.5) | 0.9 (0.8) | 0.8 (0.6) | 0.6 (0.5) | 0.7 (0.5) | 0.9 (0.7) | 0.9 (0.9) | |
| BASMI linear, 0–10, mean (SD) | r-axSpA | 2.3 (0.9) | 2.4 (1.2) | 2.4 (1.2) | 2.2 (1.3) | 2.4 (0.9) | 2.6 (1.1) | 2.2 (1.2) | 2.3 (1.2) | 2.2 (1.3) |
| nr-axSpA | 2.5 (0.8) | 2.7 (1.0) | 2.4 (0.9) | 1.7 (0.5) | 1.8 (0.8) | 1.6 (0.7) | 1.7 (0.7) | 2.1 (1.0) | 2.1 (0.9) | |
| ASDAS, mean (SD) | r-axSpA | 2.9 (0.6) | 1.5 (0.6) | 1.3 (0.7) | 1.2 (0.6) | 1.0 (0.7) | 1.0 (0.6) | 1.2 (0.7) | 1.1 (0.8) | 1.2 (0.9) |
| nr-axSpA | 3.3 (0.7) | 1.7 (0.7) | 1.4 (0.7) | 1.2 (0.9) | 0.8 (0.5) | 0.8 (0.5) | 0.9 (0.6) | 0.8 (0.5) | 0.9 (0.3) | |
| PtGA, 0–10, mean (SD) | r-axSpA | 5.8 (1.4) | 2.5 (2.2) | 2.1 (1.5) | 1.9 (1.4) | 1.7 (1.7) | 1.7 (1.4) | 1.9 (1.6) | 1.7 (1.5) | 1.9 (2.0) |
| nr-axSpA | 6.7 (2.6) | 2.6 (2.2) | 2 (2.1) | 1.7 (2.4) | 0.9 (1.1) | 1.1 (1.1) | 1 (0.8) | 0.9 (0.7) | 1.0 (1.0) | |
| PhyGA, 0–10, mean (SD) | r-axSpA | 5.4 (1.4) | 1.5 (1.7) | 1.9 (2.2) | 1.4 (1.0) | 0.8 (1.0) | 1.3 (1.8) | 1.2 (1.8) | 1.0 (1.2) | 1.0 (1.3) |
| nr-axSpA | 5.7 (1.7) | 2.1 (2.4) | 1.6 (1.6) | 1.4 (1.3) | 0.4 (0.8) | 0.6 (1.1) | 0.6 (0.5) | 0.6 (0.8) | 0.7 (0.8) | |
| Arthritis count, 0–64, mean (SD) | r-axSpA | 1.0 (1.9) | 0.2 (0.6) | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) | 0.1 (0.3) | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) |
| nr-axSpA | 3.6 (6.9) | 0.0 (0.0) | 0.1 (0.4) | 0.0 (0.0) | 0.6 (1.5) | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) | 0.1 (0.4) | |
| Enthesitis score, 0–17, mean (SD) | r-axSpA | 3.0 (3.0) | 1.4 (4.1) | 1.3 (3.2) | 0.7 (1.8) | 0.5 (1.7) | 1.1 (3.8) | 0.3 (1.2) | 0.8 (2.6) | 0.8 (1.8) |
| nr-axSpA | 2.4 (2.7) | 1.0 (2.2) | 0.6 (1.1) | 0.0 (0.0) | 0.0 (0.0) | 0.6 (1.5) | 0.3 (0.5) | 0.3 (0.5) | 0.3 (0.5) | |
| CRP, mg/L, mean (SD) | r-axSpA | 8.4 (12.5) | 1.6 (0.5) | 1.5 (0) | 2.2 (3.5) | 1.5 (2.3) | 1.2 (1.2) | 2.1 (2.7) | 2.9 (4.7) | 2.1 (2.4) |
| nr-axSpA | 5.0 (4.6) | 2.8 (3.4) | 2.4 (2.3) | 2.2 (2.6) | 2.7 (5.8) | 2.4 (5.1) | 2.4 (4.8) | 1.8 (2.7) | 1.5 (1.7) | |
| ASAS 20, % | r-axSpA | NA | 75 | 75 | 83.3 | 75 | 83.3 | 83.3 | 83.3 | 83.3 |
| nr-axSpA | NA | 85.7 | 100 | 100 | 85.7 | 100 | 100 | 100 | 100 | |
| ASAS 40, % | r-axSpA | NA | 58.3 | 66.7 | 66.7 | 75 | 83.3 | 66.7 | 83.3 | 66.7 |
| nr-axSpA | NA | 57.1 | 71.4 | 85.7 | 85.7 | 85.7 | 100 | 85.7 | 100 | |
| ASAS 5/6, % | r-axSpA | NA | 41.7 | 33.3 | 58.3 | 75 | 83.3 | 58.3 | 83.3 | 66.7 |
| nr-axSpA | NA | 42.9 | 57.1 | 71.4 | 85.7 | 85.7 | 71.4 | 85.7 | 71.4 | |
| ASAS Partial remission, % | r-axSpA | NA | 41.7 | 50 | 58.3 | 58.3 | 66.7 | 50 | 66.7 | 66.7 |
| nr-axSpA | NA | 57.1 | 71.4 | 71.4 | 71.4 | 57.1 | 85.7 | 71.4 | 57.1 | |
| BASDAI50, % | r-axSpA | NA | 58.3 | 58.3 | 66.7 | 75 | 83.3 | 75 | 75 | 66.7 |
| nr-axSpA | NA | 42.9 | 85.7 | 85.7 | 100 | 100 | 100 | 100 | 100 | |
| BASDAI <3, % | r-axSpA | 0 | 58.3 | 58.3 | 75 | 83.3 | 83.3 | 83.3 | 83.3 | 66.7 |
| nr-axSpA | 0 | 42.9 | 71.4 | 85.7 | 100 | 100 | 100 | 100 | 100 | |
| ASDAS inactive disease, % | r-axSpA | NA | 41.7 | 50.0 | 58.3 | 66.7 | 75.0 | 50 | 75 | 58.3 |
| nr-axSpA | NA | 28.6 | 57.1 | 57.1 | 71.4 | 85.7 | 71.4 | 71.4 | 85.7 | |
| ASDAS major improvement, % | r-axSpA | NA | 33.3 | 41.7 | 33.3 | 33.3 | 33.3 | 25 | 33.3 | 41.7 |
| nr-axSpA | NA | 14.3 | 14.3 | 14.3 | 28.6 | 28.6 | 14.3 | 28.6 | 42.9 |
ASAS, Assessment of SpondyloArthritis international Society; ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Mobility Index; CRP, C-reactive protein; NA, not applicable; r-axSpA, radiographic axial spondyloarthritis; nr-axSpA, non-radiographic axial spondyloarthritis; PhGA, physician’s global assessment; PGA, patient’s global assessment; SD, standard deviation.